Analysts Set Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Price Target at $1.35

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) has received a consensus recommendation of “Reduce” from the eight brokerages that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $1.3517.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adaptimmune Therapeutics in a research note on Wednesday, October 8th.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Large investors have recently modified their holdings of the stock. Susquehanna International Group LLP grew its holdings in shares of Adaptimmune Therapeutics by 491.5% during the 3rd quarter. Susquehanna International Group LLP now owns 308,065 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 255,980 shares during the period. Bank of America Corp DE boosted its position in shares of Adaptimmune Therapeutics by 15.6% during the third quarter. Bank of America Corp DE now owns 1,319,669 shares of the biotechnology company’s stock valued at $172,000 after purchasing an additional 177,956 shares in the last quarter. UBS Group AG boosted its holdings in shares of Adaptimmune Therapeutics by 10,490.2% during the 3rd quarter. UBS Group AG now owns 6,667,358 shares of the biotechnology company’s stock valued at $867,000 after buying an additional 6,604,400 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in Adaptimmune Therapeutics during the 3rd quarter valued at about $65,000. Finally, Two Seas Capital LP boosted its stake in Adaptimmune Therapeutics by 10.0% during the second quarter. Two Seas Capital LP now owns 22,580,701 shares of the biotechnology company’s stock worth $5,413,000 after acquiring an additional 2,051,016 shares in the last quarter. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Stock Performance

NASDAQ ADAP opened at $0.06 on Wednesday. The stock has a market cap of $15.35 million, a P/E ratio of -0.09 and a beta of 2.49. Adaptimmune Therapeutics has a fifty-two week low of $0.04 and a fifty-two week high of $0.86. The stock has a 50 day simple moving average of $0.10 and a two-hundred day simple moving average of $0.15.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.